by TractManager | Feb 27, 2018 | Health Technology Assessment
Health Problem: Central line-associated bloodstream infections (CLABSIs) have a high rate of mortality among hospital-acquired infections. These infections pose such a high risk because patients who require central venous catheters (CVCs) are usually acutely ill or...
by TractManager | Feb 23, 2018 | Health Technology Assessment
Health Problem: Dry eye disease (DED) is a group of tear film disorders attributed to reduced tear production or excessive tear evaporation and associated with ocular discomfort, visual symptoms, and possible disease of the ocular surface. DED is estimated to be...
by TractManager | Feb 22, 2018 | Health Technology Assessment
Health Problem: Coronary artery disease (CAD) is responsible for serious harms, including myocardial infarction (MI) and death. It is characterized by atherosclerosis, the thickening and hardening of arteries due to plaque buildup. Atherosclerosis results from the...
by TractManager | Feb 16, 2018 | Clinical Utility Evaluation
This report evaluates the clinical utility for use of cell-free DNA (cfDNA) screening for fetal trisomy 21, 18, and 13 in high-risk women with singleton or multiple gestation pregnancies. Populations at high risk for aneuploidy include women with advanced maternal...
by TractManager | Feb 15, 2018 | Emerging Technology Report
Erleada is an oral androgen receptor inhibitor approved by the FDA for the treatment of nonmetastatic castration-resistant prostate cancer.If you have a Hayes login, click here to view the full report on the Knowledge Center.
Recent Comments